GRIFOLS S.A. (GRF.MC)

Key Updates

Grifols shares recovered 2.01% to $8.82 since the March 26 report, partially offsetting recent declines but remaining down 17.55% YTD. The company faces heightened regulatory scrutiny as it prepares to testify before Canadian lawmakers on March 26 regarding two patient deaths at its Winnipeg plasma collection centers, though Health Canada has found no link between the donation process and the fatalities. Despite this reputational challenge, the planned U.S. biopharma IPO remains on track for the second half of 2026, targeting $4-5 billion in proceeds to strengthen the balance sheet.

Current Trend

Grifols remains in a pronounced downtrend with YTD losses of 17.55% and 6-month losses of 28.42%. The stock has experienced severe volatility, declining 17.01% over the past month before the modest 2.01% recovery. Short-term momentum shows stabilization with 5-day performance at +0.16%, suggesting potential consolidation near current levels. The current price of $8.82 represents a critical juncture, with the stock attempting to establish support after significant selling pressure. The 1-month decline accelerated following the IPO announcement, indicating investor concerns about dilution and execution risk have outweighed the potential balance sheet benefits.

Investment Thesis

The investment thesis centers on Grifols' strategic restructuring through the U.S. biopharma unit IPO, which could unlock substantial value by creating transparency around its core plasma business valued at up to $27 billion—nearly four times the parent company's current market capitalization of €5.8 billion. The company reported strong operational performance in February 2026, with 2025 profit more than doubling and projected core earnings growth exceeding 25% in 2026. The creation of the first fully self-sufficient U.S. plasma player, independent of external plasma, manufacturing, or supply sources, positions Grifols uniquely in a market valued at $40.35 billion and expected to double over the next eight years. However, execution risks include regulatory scrutiny following the Canadian deaths, successful IPO completion amid market volatility, and managing debt reduction while maintaining operational growth.

Thesis Status

The investment thesis faces near-term headwinds but remains structurally intact. The Canadian parliamentary inquiry introduces reputational risk at a critical juncture before the IPO, though Health Canada's preliminary findings showing no link to the donation process mitigate some concerns. The market's negative reaction to the IPO announcement—with shares declining 14% in 2026 prior to the recent recovery—suggests investors are pricing in execution risk and potential dilution rather than focusing on the value unlock opportunity. The substantial valuation gap between the U.S. unit ($27 billion potential valuation) and the parent company (€5.8 billion market cap) supports the thesis that the IPO could improve price discovery and unlock shareholder value. The thesis requires successful navigation of the Canadian inquiry and strong IPO execution in the second half of 2026.

Key Drivers

The most critical near-term driver is Grifols' testimony before Canadian lawmakers on March 26 regarding two patient deaths at Winnipeg plasma centers, which could impact the company's reputation and regulatory standing despite Health Canada finding no link between donations and fatalities (Bloomberg). The planned U.S. biopharma IPO targeting $4-5 billion in proceeds through listing approximately 20% of the Los Angeles-based unit on Nasdaq remains the transformative catalyst, with the subsidiary potentially valued at $27 billion including debt (Bloomberg). The IPO proceeds will strengthen the balance sheet and support debt reduction efforts, building on February's report of 2025 profit more than doubling and projected 2026 core earnings growth exceeding 25% (Reuters). Industry dynamics remain favorable, with plasma-derived medicinal products valued at $40.35 billion and expected to double over the next eight years, driven by expanding use in treating immune deficiency syndromes and bleeding disorders (NYT).

Technical Analysis

Grifols shares are attempting to stabilize at $8.82 after a severe 17.01% monthly decline, with the 2.01% recovery since the last report suggesting potential short-term support formation. The stock has experienced extreme volatility, declining 28.42% over six months and 17.55% YTD, indicating sustained selling pressure. Near-term momentum shows signs of stabilization with 5-day performance at +0.16% and 1-day performance at +1.08%, though this follows significant losses. The current price level represents a critical test of support, with the stock trading significantly below recent highs. Volume and sentiment dynamics around the March 26 Canadian parliamentary testimony will likely determine whether this stabilization represents a genuine floor or a temporary pause in the downtrend. Resistance levels will be established by the market's assessment of IPO execution risk and the outcome of regulatory scrutiny.

Bull Case

• The U.S. biopharma IPO could unlock substantial value with the subsidiary potentially valued at $27 billion—nearly four times the parent company's current €5.8 billion market capitalization, suggesting significant undervaluation that could be corrected through improved price discovery (Bloomberg).
• Strong operational momentum with 2025 profit more than doubling and projected 2026 core earnings growth exceeding 25%, demonstrating robust underlying business performance despite share price weakness (Reuters).
• The plasma-derived medicinal products market is valued at $40.35 billion and expected to double over the next eight years, providing strong secular tailwinds for Grifols' core business driven by expanding therapeutic applications (NYT).
• The IPO will raise $4-5 billion to strengthen the balance sheet and accelerate deleveraging, addressing a key investor concern and improving financial flexibility for future growth investments (Bloomberg).
• Health Canada found no link between the donation process and the two patient deaths at Winnipeg facilities, allowing both centers to continue operations and potentially mitigating reputational concerns ahead of the parliamentary inquiry (Bloomberg).

Bear Case

• Grifols faces parliamentary testimony on March 26 regarding two patient deaths at its Canadian plasma centers, creating reputational risk and potential regulatory headwinds at a critical juncture before the planned IPO (Bloomberg).
• The stock has declined 17.55% YTD and 28.42% over six months, with shares down 14% in 2026 prior to the recent recovery, indicating persistent investor concerns about revenue growth and execution risk that may not be resolved by the IPO alone (Bloomberg).
• The U.S. biopharma unit represents the bulk of group earnings with nearly €6.5 billion in 2025 revenue, meaning the IPO introduces execution risk and potential dilution concerns that could offset balance sheet benefits if market conditions deteriorate (Bloomberg).
• Industry safety concerns highlighted by The New York Times regarding frequent plasma donation practices could lead to increased regulatory scrutiny across the sector, potentially impacting collection volumes and operational costs (NYT).
• The IPO is targeted for the second half of 2026, creating an extended period of uncertainty during which market conditions could deteriorate, regulatory challenges could intensify, or competitive dynamics could shift unfavorably (Reuters).